MX9700222A - Derivados de camptotecina. - Google Patents

Derivados de camptotecina.

Info

Publication number
MX9700222A
MX9700222A MX9700222A MX9700222A MX9700222A MX 9700222 A MX9700222 A MX 9700222A MX 9700222 A MX9700222 A MX 9700222A MX 9700222 A MX9700222 A MX 9700222A MX 9700222 A MX9700222 A MX 9700222A
Authority
MX
Mexico
Prior art keywords
derivatives
camptothecin derivatives
camptothecin
group
campthothecin
Prior art date
Application number
MX9700222A
Other languages
English (en)
Other versions
MXPA97000222A (es
Inventor
Kenji Tsujihara
Takayuki Kawaguchi
Satoshi Okuno
Toshiro Yano
Original Assignee
Tanabe Seiyaku Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tanabe Seiyaku Co filed Critical Tanabe Seiyaku Co
Publication of MXPA97000222A publication Critical patent/MXPA97000222A/es
Publication of MX9700222A publication Critical patent/MX9700222A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0018—Pullulan, i.e. (alpha-1,4)(alpha-1,6)-D-glucan; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0021—Dextran, i.e. (alpha-1,4)-D-glucan; Derivatives thereof, e.g. Sephadex, i.e. crosslinked dextran

Abstract

Un derivado de camptotecina que comprende un compuesto de la formula [I]. En donde R1, R2, R3, R4 Y R5 son (A) dos grupos adyacentes que combinan para formar alquileno, o ambos son H, y uno de los tres grupos restante es -Xn-A1qm-R6, y los otros dos son H, alquilo o halogeno, o (B) dos grupos adyacentes se combinan para formar alquileno, y uno de los átomos de carbono de dicho grupo alquileno es substituido por -Xn-A1qm-R6, y los tres grupos restantes son H, alquilo o halogeno, y uno de los -CH2- de alquileno en (A) o (B) pueden ser opcionalmente reemplazados por -O-, -S- o -NH-, X es -O- o -NH-, Alq es alquileno, R6 es NH2, formula pág. 55 m y n son ambos 0 o 1, o m es 1 y n es 0, dicho compuesto de camptotecina está enlazado a un polisacárido que tiene grupos carboxilo a través de un aminoácido o un péptido, o una sal farmacéuticamente aceptable del mismo. Dichos derivados de camptotecina muestran actividades antitumorales incrementadas pero pocos efectos laterales y con utiles como un medicamento.
MX9700222A 1995-12-28 1997-01-07 Derivados de camptotecina. MX9700222A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP34357595 1995-12-28
JP7-343575 1995-12-28
JP20010596 1996-07-30
JP8-200105 1996-07-30

Publications (2)

Publication Number Publication Date
MXPA97000222A MXPA97000222A (es) 1998-04-01
MX9700222A true MX9700222A (es) 1998-04-30

Family

ID=26511972

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9700222A MX9700222A (es) 1995-12-28 1997-01-07 Derivados de camptotecina.

Country Status (15)

Country Link
US (3) US5892043A (es)
EP (1) EP0781781B1 (es)
KR (1) KR100352545B1 (es)
CN (2) CN1142935C (es)
AT (1) ATE206720T1 (es)
CA (1) CA2192725C (es)
DE (1) DE69615808T2 (es)
DK (1) DK0781781T3 (es)
ES (1) ES2164218T3 (es)
GR (1) GR3037076T3 (es)
ID (1) ID25979A (es)
MX (1) MX9700222A (es)
PT (1) PT781781E (es)
SG (2) SG49994A1 (es)
TW (1) TW473478B (es)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5888988A (en) * 1995-05-08 1999-03-30 Chitogenics, Inc. Covalently linked N,O-carboxymethylchitosan and uses thereof
CA2192725C (en) 1995-12-28 2004-04-20 Kenji Tsujihara Camptothecin derivatives
US6096336A (en) * 1996-01-30 2000-08-01 The Stehlin Foundation For Cancer Research Liposomal prodrugs comprising derivatives of camptothecin and methods of treating cancer using these prodrugs
US6441025B2 (en) * 1996-03-12 2002-08-27 Pg-Txl Company, L.P. Water soluble paclitaxel derivatives
DE19640207A1 (de) * 1996-09-30 1998-04-02 Bayer Ag Glycokonjugate von modifizierten Camptothecin-Derivaten (A- oder B-Ring-Verknüpfung)
JP2001504453A (ja) * 1996-09-30 2001-04-03 バイエル・アクチエンゲゼルシヤフト 改変カンプトテシン誘導体からの複合糖質（２０―ｏ―結合）
SG116433A1 (en) 1996-10-30 2005-11-28 Tanabe Seiyaku Co S type 2-substituted hydroxy-2-indolidinylbutyric ester compounds and process for preparation thereof.
ID23424A (id) * 1997-05-14 2000-04-20 Bayer Ag Glikokonjugat dari 20(s)-kamptotesin
EP1080732A4 (en) * 1998-05-22 2004-08-25 Daiichi Seiyaku Co DRUG COMPOSITION
US6043367A (en) * 1998-09-30 2000-03-28 Roffler; Steve Proactive antitumor compounds
WO2000030664A1 (en) * 1998-11-25 2000-06-02 Nutri Pharma Asa Composition comprising soy protein, dietary fibres and a phytoestrogen compound and use thereof in the prevention and/or treatment of pulmonary diseases
US6352996B1 (en) 1999-08-03 2002-03-05 The Stehlin Foundation For Cancer Research Liposomal prodrugs comprising derivatives of camptothecin and methods of treating cancer using these prodrugs
US6228855B1 (en) 1999-08-03 2001-05-08 The Stehlin Foundation For Cancer Research Aromatic esters of camptothecins and methods to treat cancers
EP1229934B1 (en) 1999-10-01 2014-03-05 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
US20030054977A1 (en) * 1999-10-12 2003-03-20 Cell Therapeutics, Inc. Manufacture of polyglutamate-therapeutic agent conjugates
SG147286A1 (en) * 1999-10-12 2008-11-28 Cell Therapeutics Inc Manufacture of polyglumate-therapeutic agent conjugates
US20040009229A1 (en) * 2000-01-05 2004-01-15 Unger Evan Charles Stabilized nanoparticle formulations of camptotheca derivatives
US20020077290A1 (en) * 2000-03-17 2002-06-20 Rama Bhatt Polyglutamic acid-camptothecin conjugates and methods of preparation
TWI313609B (en) * 2001-08-21 2009-08-21 Mitsubishi Tanabe Pharma Corp Pharmaceutical composition for inhibiting the metastasis or preventing the recurrence of malignant tumor
US20030092608A1 (en) * 2001-08-21 2003-05-15 Takayuki Kawaguchi Pharmaceutical composition for inhibiting the metastasis or preventing the recurrence of malignant tumor
CN100393724C (zh) * 2002-07-12 2008-06-11 中国医学科学院药物研究所 20-位酯化的喜树碱衍生物及其制法和其药物组合物与用途
US20040204435A1 (en) * 2003-04-09 2004-10-14 Joachim Liehr Alternating treatment with topoisomerase I and topoisomerase II inhibitors
ITRM20040240A1 (it) 2004-05-13 2004-08-13 Ist Naz Stud Cura Dei Tumori Camptotecine coniugate in posizione 7 con antagonisti delle integrine.
WO2006027567A2 (en) * 2004-09-07 2006-03-16 Biocompatibles Uk Limited Drug delivery from embolic agents
ITPD20050242A1 (it) 2005-08-03 2007-02-04 Fidia Farmaceutici Bioconiugati antitumorali dell'acido ialuronico o dei suoi derivati, ottenibili per coniugazione chimica diretta o indiretta, e loro impiego in campo farmaceutico
FR2914305B1 (fr) * 2007-03-29 2009-07-03 Proteins & Peptides Man Dextran fonctionnalise par des amino-acides hydrophobes.
FR2891149B1 (fr) * 2005-09-26 2007-11-30 Biodex Sarl Composition pharmaceutique a action cicatrisante comprenant un derive de dextrane soluble et un facteur de croissance derive des plaquettes.
FR2919188B1 (fr) * 2007-07-27 2010-02-26 Proteins & Peptides Man Complexes entre un polymere amphiphile et une proteine osteogenique appartenant a la famille des bmps
CN115960111A (zh) 2012-10-11 2023-04-14 第一三共株式会社 抗体－药物偶联物
EP2910573B1 (en) 2012-10-19 2020-02-19 Daiichi Sankyo Company, Limited Antibody-drug conjugate produced by binding through linker having hydrophilic structure
CA2933666C (en) 2013-12-25 2021-08-03 Sapporo Medical University Anti-trop2 antibody-drug conjugate
IL310627A (en) 2014-01-31 2024-04-01 Daiichi Sankyo Company Ltd Anti-HER2 drug-antibody conjugates, preparations containing them and their uses
SG10201907807XA (en) 2014-04-10 2019-09-27 Daiichi Sankyo Co Ltd Anti-her3 antibody-drug conjugate
WO2015155976A1 (ja) 2014-04-10 2015-10-15 第一三共株式会社 抗ｈｅｒ２抗体－薬物コンジュゲート
JP6787890B2 (ja) 2015-06-29 2020-11-18 第一三共株式会社 抗体−薬物コンジュゲートの選択的製造方法
WO2018110515A1 (ja) 2016-12-12 2018-06-21 第一三共株式会社 抗体－薬物コンジュゲートと免疫チェックポイント阻害剤の組み合わせ
AU2018210081A1 (en) 2017-01-17 2019-08-08 Daiichi Sankyo Company, Limited Anti-GPR20 antibody and anti-GPR20 antibody-drug conjugate
TW202330036A (zh) 2017-05-15 2023-08-01 日商第一三共股份有限公司 抗體-藥物結合物之製造方法
CN117865839A (zh) 2017-08-31 2024-04-12 第一三共株式会社 制备抗体-药物缀合物的新方法
CA3073924C (en) 2017-08-31 2023-10-17 Daiichi Sankyo Company, Limited Improved method for producing antibody-drug conjugate
CA3100745A1 (en) 2018-05-18 2019-11-21 Glycotope Gmbh Anti-muc1 antibody
CN113952465A (zh) * 2021-10-20 2022-01-21 中国药科大学 一种喜树碱前药及其制备方法和应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0220601B1 (en) 1985-10-21 1991-12-11 Daiichi Seiyaku Co., Ltd. Pyranoindolizine derivatives and preparation process thereof
US5180722A (en) 1987-04-14 1993-01-19 Research Triangle Institute 10,11-methylenedioxy-20(RS)-camptothecin and 10,11-methylenedioxy-20(S)-camptothecin analogs
JP2540357B2 (ja) 1987-06-24 1996-10-02 第一製薬株式会社 六環性化合物
IT1240314B (it) 1989-09-28 1993-12-07 Immunobiology Research Institutes, Inc. Formulazioni acquose stabilizzate di piccoli peptidi.
DK0540099T3 (da) 1991-10-29 1996-06-17 Glaxo Wellcome Inc Vandopløselige camptothecinderivater
JPH06228141A (ja) 1992-01-24 1994-08-16 Takeda Chem Ind Ltd 縮合複素環誘導体、その塩、その製造法および用途
JP3359955B2 (ja) 1992-07-16 2002-12-24 第一製薬株式会社 抗腫瘍剤
WO1994019376A1 (en) 1993-02-26 1994-09-01 Drug Delivery System Institute, Ltd. Polysaccharide derivative and drug carrier
GB9320781D0 (en) 1993-10-08 1993-12-01 Erba Carlo Spa Polymer-bound camptothecin derivatives
SG50747A1 (en) 1995-08-02 1998-07-20 Tanabe Seiyaku Co Comptothecin derivatives
CA2192725C (en) 1995-12-28 2004-04-20 Kenji Tsujihara Camptothecin derivatives

Also Published As

Publication number Publication date
ID25979A (id) 1997-06-26
CN1300733A (zh) 2001-06-27
DK0781781T3 (da) 2001-11-26
US5892043A (en) 1999-04-06
PT781781E (pt) 2002-03-28
DE69615808T2 (de) 2002-05-02
EP0781781A3 (en) 1998-04-01
GR3037076T3 (en) 2002-01-31
EP0781781A2 (en) 1997-07-02
US6617456B1 (en) 2003-09-09
KR970042553A (ko) 1997-07-24
US6512118B1 (en) 2003-01-28
DE69615808D1 (de) 2001-11-15
CN1142935C (zh) 2004-03-24
SG76585A1 (en) 2000-11-21
CA2192725C (en) 2004-04-20
CA2192725A1 (en) 1997-06-29
CN1073113C (zh) 2001-10-17
SG49994A1 (en) 1998-06-15
KR100352545B1 (ko) 2003-01-24
CN1158334A (zh) 1997-09-03
EP0781781B1 (en) 2001-10-10
ES2164218T3 (es) 2002-02-16
TW473478B (en) 2002-01-21
ATE206720T1 (de) 2001-10-15

Similar Documents

Publication Publication Date Title
MX9700222A (es) Derivados de camptotecina.
DE69432758D1 (en) Therapeutisch wirksame peptidderivate
DE69912952D1 (en) Cyclosporine
CA2182244A1 (en) Camptothecin derivatives
CA2129288A1 (en) Phosphonooxymethyl Esters of Taxane Derivatives
SG44794A1 (en) Novel peptide derivatives
ES2173480T3 (es) Preparacion de derivados de ciclohexeno carboxilato.
ID23374A (id) Halogenopirimidin
GB0401088D0 (en) Phosphoramidate derivatives
ES2169414T3 (es) Amino-azucar citotoxico y derivados de azucares relacionados de indolopirrolocarbazoles.
ATE176464T1 (de) Semisynthetisch taxal derivate mit antitumor wirkung
DE69625354D1 (de) Relaxinartiger faktor und damit zusammenhängende verfahren und verwendungen
AU2002360421A1 (en) Modular system for coating plastics
MY133112A (en) 3-amino-3-arylpropan-1-ol derivatives, and their preparation and use
ATE208774T1 (de) Arylsulfonylimidazolon-derivate als antitumormittel
DE60133198D1 (en) Glykopeptidderivate mit carboxysacchariden
ES8605769A1 (es) Un procedimiento para la preparacion de un peptido
DE69619530T2 (de) Zyklische somatostatinanaloge mit wachstumhormon inhibierender aktivität
IT1290444B1 (it) Coniugati di bis-fosfonati con funzionalita' alchilanti aventi attivita' antitumorale
EP0739883A4 (en) UCF116 COMPOUNDS
DK1117393T3 (da) L-acetylcarnitin som antitumorpræparat
AU1192097A (en) 3-aminoethyl-n-amidino-2,5-dihydropyrrole derivatives having arginine mimetic properties
BR0208322A (pt) Derivados de açúcar citotóxixo seletivo da topoisomerase i de indolopirrolocarbazóis
IT1247879B (it) 6,9-bis (amino sostituiti) benzo(g) ftalazin-5,10-dioni come farmaci antitumorali.